Ibrexafungerp is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
At SCYNEXIS, we believe that ibrexafungerp could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more. Learn more about our pipeline below.
Learn more about our commitment to protecting the world against dangerous and difficult-to-treat infectious diseases.
Learn MoreSCYNEXIS regularly presents key infectious disease study data at top medical meetings.
Learn More